Close Menu
Global News HQ
    What's Hot

    Client Challenge

    December 16, 2025

    MetaMask adds Bitcoin support after teasing it 10 months ago

    December 16, 2025

    Morning meetings show managers are here to help, not hinder

    December 16, 2025
    Recent Posts
    • Client Challenge
    • MetaMask adds Bitcoin support after teasing it 10 months ago
    • Morning meetings show managers are here to help, not hinder
    • Insurance moves at Starkweather & Shepley and Amica Mutual
    • Chickenpox in Adults: Risk Factors, Symptoms, Complications, Treatment
    Facebook X (Twitter) Instagram YouTube TikTok
    Trending
    • Client Challenge
    • MetaMask adds Bitcoin support after teasing it 10 months ago
    • Morning meetings show managers are here to help, not hinder
    • Insurance moves at Starkweather & Shepley and Amica Mutual
    • Chickenpox in Adults: Risk Factors, Symptoms, Complications, Treatment
    • First-Year Law School Enrollees Increase 13% Since 2023| Law.com
    • The Potato Board Is the Ultimate Crowd-Pleasing Appetizer This Holiday Season
    • Silksong is getting a free expansion next year
    Global News HQ
    • Technology & Gadgets
    • Travel & Tourism (Luxury)
    • Health & Wellness (Specialized)
    • Home Improvement & Remodeling
    • Luxury Goods & Services
    • Home
    • Finance & Investment
    • Insurance
    • Legal
    • Real Estate
    • More
      • Cryptocurrency & Blockchain
      • E-commerce & Retail
      • Business & Entrepreneurship
      • Automotive (Car Deals & Maintenance)
    Global News HQ
    Home - Health & Wellness (Specialized) - GLP-1 Agonists: Using Semaglutide and Tirzepatide for Weight Loss and Obesity
    Health & Wellness (Specialized)

    GLP-1 Agonists: Using Semaglutide and Tirzepatide for Weight Loss and Obesity

    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    GLP-1 Agonists: Using Semaglutide and Tirzepatide for Weight Loss and Obesity
    Share
    Facebook Twitter LinkedIn Pinterest Email


    GLP-1 drugs are associated with a wide variety of side effects.

    Common Side Effects

    Gastrointestinal distress is the most common side effect reported by people who take GLP-1s, and is experienced by a high percentage of users. Nausea and diarrhea are most common, followed by constipation, vomiting, and abdominal pain.

    In the majority of people in clinical trials, these side effects have been mild or moderate. Gastrointestinal issues are usually strongest in first-time users, or when people step up to a larger dosage, but they usually dissipate over time. A small number of users may experience gastrointestinal effects so severe that they need to stop taking the medication.

    Rare, More Serious Side Effects

    Other side effects are much more rare, but potentially serious. GLP-1 agonists can cause inflammation of the pancreas, called pancreatitis, bowel obstruction, and gastroparesis (paralysis of the stomach).

    In people who are allergic or hypersensitive to GLP-1s, the drug can cause anaphylaxis, a dangerous reaction that can involve the rapid onset of hives, swelling, and even loss of consciousness.

    GLP-1 drugs can also create a risk of hypoglycemia, or dangerously low blood sugar, in people who use certain type 2 diabetes drugs, chiefly insulin and sulfonylureas.

    Anecdotal Side Effects

    There has also been plenty of media buzz about anecdotal side effects with names like “Ozempic face” and “Ozempic butt.”

    These cosmetic side effects aren’t unhealthy, and aren’t directly caused by GLP-1s. Instead, they are caused by rapid significant weight loss.

    Weight loss can make parts of your body look different. While your belly may slim down, so might your buttocks and face. In some people, weight loss can lead to looser or sagging skin. Weight loss can also cause hair loss, and may be responsible for other rarely reported side effects, such as tiredness.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleDogecoin and BNB Rise as Bitcoin, Ethereum Hit Highest Prices This Month – Decrypt
    Next Article Agent Washed: Unpacking the Hype and Reality of Legal AI Agents | Law.com

    Related Posts

    Chickenpox in Adults: Risk Factors, Symptoms, Complications, Treatment

    December 16, 2025

    This Device Is My Secret Weapon for Depuffing, Lymphatic Drainage, and Feeling Recharged

    December 16, 2025

    How Creatine Helps Your Brain Perform Better Under Stress

    December 15, 2025

    11 Icky but Interesting Facts About Poop

    December 14, 2025
    Leave A Reply Cancel Reply

    ads
    Don't Miss
    Finance & Investment
    1 Min Read

    Client Challenge

    Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required…

    MetaMask adds Bitcoin support after teasing it 10 months ago

    December 16, 2025

    Morning meetings show managers are here to help, not hinder

    December 16, 2025

    Insurance moves at Starkweather & Shepley and Amica Mutual

    December 16, 2025
    Top
    Finance & Investment
    1 Min Read

    Client Challenge

    Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required…

    MetaMask adds Bitcoin support after teasing it 10 months ago

    December 16, 2025

    Morning meetings show managers are here to help, not hinder

    December 16, 2025
    Our Picks
    Finance & Investment
    1 Min Read

    Client Challenge

    Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required…

    Cryptocurrency & Blockchain
    2 Mins Read

    MetaMask adds Bitcoin support after teasing it 10 months ago

    Crypto wallet giant MetaMask has announced it has added support for Bitcoin, hinting that more…

    Pages
    • About Us
    • Contact Us
    • Disclaimer
    • Homepage
    • Privacy Policy
    Facebook X (Twitter) Instagram YouTube TikTok
    • Home
    © 2025 Global News HQ .

    Type above and press Enter to search. Press Esc to cancel.

    Go to mobile version